CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines
CONMED (NYSE:CNMD) had its price target lowered by analysts at JPMorgan Chase & Co. from $58.00 to $52.00. They now have a "neutral" rating on the stock.
CONMED (NYSE:CNMD) had its price target lowered by analysts at Piper Sandler from $68.00 to $55.00. They now have an "overweight" rating on the stock.
CONMED (NYSE:CNMD) had its price target lowered by analysts at Wells Fargo & Company from $57.00 to $47.00. They now have an "equal weight" rating on the stock.
Conmed Corp (CNMD) Q3 2025 Earnings Call Highlights: Strong Sales Growth Amidst Margin Challenges [Yahoo! Finance]